Immunomodulatory Molecules On Lung Cancer Stem Cells From Lymph Nodes Aspirates

Over the past decade, immune checkpoint inhibitors have revolutionized the treatment of non-small cell lung cancer (NSCLC). Unfortunately, not all patients benefit from PD-(L)1 blockade, yet, the PD-L1 tumor cell expression is the only approved biomarker, and other biomarkers have been investigated....

Descripción completa

Detalles Bibliográficos
Autores principales: Raniszewska, Agata, Kwiecień, Iwona, Sokołowski, Rafał, Rutkowska, Elżbieta, Domagała-Kulawik, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226167/
https://www.ncbi.nlm.nih.gov/pubmed/32244422
http://dx.doi.org/10.3390/cancers12040838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226167/
https://www.ncbi.nlm.nih.gov/pubmed/32244422
http://dx.doi.org/10.3390/cancers12040838

Ejemplares similares